VulvodyniaPhase 3DMLPVNCT02393911
Dysbiosis in Localized Provoked Vulvodynia (LPV)
A Phase 3 study testing Low Oxalate Diet in people with Vulvodynia and Vulvar Vestibulitis, run by Western Galilee Hospital-Nahariya.
Trial summary
Currently, the pathogenesis of Localized Provoked Vulvodynia (LPV) has not been elucidated. Few observations may point to involvement of the microbiome: the association of LPV with preceding chronic recurrent candidiasis, and the reports of the beneficial effect of a diet avoiding oxalate on Vulvodynia. Read more about this study
- Who is it for?
- Ages 18 to 50 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- Vulvodynia, Vulvar Vestibulitis
- What is being tested?
- Low Oxalate Diet
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 70 participants
- Where
- No sites listed yet
- Study dates
- Mar 2015to Feb 2017
- Phase
- Phase 3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 50 years
- Women only
- Healthy volunteers accepted
- Adult
Who may be able to join
- Healthy women, aged 18-50 years, meet Friedrich's first two criteria for vulvar Vestibulitis syndrome, suffer from levels II or III dyspareunia according to Marinoff
Who cannot join
- Women suffering from generalized Vulvodynia (constant vulvar pain - unrelated to provocation), pregnant or lactating. Women will also be excluded from the study if they were have any medical condition, acute or chronic, or anticipated not being available for the one month follow up visit, have received antibiotics during the month preceding the study.
Trial locations and contacts
No sites are listed yet.
About this study
Official title: Dysbiosis in the Vaginal Microbiota May be Associated With the Development of Localized Provoked Vulvodynia (LPV)
Currently, the pathogenesis of Localized Provoked Vulvodynia (LPV) has not been elucidated. Few observations may point to involvement of the microbiome: the association of LPV with preceding chronic recurrent candidiasis, and the reports of the beneficial effect of a diet avoiding oxalate on Vulvodynia.
Studies in the new field of microbiome research focus on the composition of overall microorganisms in our body and their impacts on our health. Changes in the composition of the vaginal microbiota (dysbiosis) have been linked with different health and disease states. We have also shown recently that women can be divided into 2 groups according to the composition of their vaginal microbiome.
The proposed study will compare the vaginal microbiome of women with severe LPV, not treated by diet and otherwise healthy, to women without LPV (we will also compare our results to the NIH HMP data). Vaginal pH and date of menstrual cycle will be checked. We propose that dysbiosis in the vaginal microbiota may trigger the development of LPV.
Read the detailed description
Vulvodynia - vulvar pain. The exact etiology has not been elucidated yet, and therapy is often unsatisfactory. Two main types of Vulvodynia exist, with the far more common type being Localized provoked vulvodynia (LPV), also known as Vestibulodynia, and in the past - Vestibulitis. This study will concentrate on this common disorder which affects young women, whose quality of life deteriorate significantly by the inability to experience vaginal sex.
The vaginal microbiome The new field of microbiome research focuses on the composition of overall microorganisms in the human body and their impacts on our human health. Amazingly, the number of microbial cells within our body is 10 times greater than the sum of all our human somatic and germ cells, and they carry 150 times more genetic information than our own. Changes in the composition of the vaginal microbiota (dysbiosis) have been linked with different health and disease states.
The vagina is colonized with around 108-109 bacteria/mL vaginal fluid which is comparable to the small intestine. Recently, the NIH Human Microbiome Project characterized the bacterial communities across the human body and found that the vagina harbors low complexity bacterial communities. These communities had the lowest alpha diversity (within sample diversity) among the different body sites and low beta diversity (between sample diversity) at the genus level. This diversity was high at the species level due to distinct Lactobacillus spp. The communities were sampled at the sub sites that included the posterior fornix, mid vagina and the vaginal introitus. There was little distinction between the three sites hence we will focus on posterior fornix. The vaginal communities of healthy women, have also been repeatedly observed to occupy one of five states, four dominated by Lactobacillus spp. and one by higher overall microbial diversity. Shifts between the community structures within individuals (dysbiosis) are associated with disease states so it would be interesting to study whether women with LPV belong to a different enterotype than healthy women.
The vaginal microbial communities have been shown to change during different stages in a woman's life and to influence pregnancy. As early as 1930, Cruickshank and Baird described changes in the vaginal bacterial communities that occurred between the 5th and 7th month of pregnancy.
In 2010 a study was undertaken among Amerindian women to examine the microbial vaginal signature at term in relation to delivery mode (n=9). Variability in vaginal taxa was noted between subjects particularly for Lactobacillus species. Metagenomic analysis of the vaginal microbiome in a cross-sectional study of 24 healthy pregnant women and 60 non-pregnant controls at three vaginal sites (introitus, posterior fornix and midvagina) found the richness and diversity of the vaginal microbiome to be reduced in pregnancy in ways that did not appear to be driven by BMI, race or ethnicity . As pregnancy progressed and as proximity to the uterus increased, less diversity and richness were noted. Lactobacillus species were enriched in pregnancy, which the authors postulated may be biologically significant as lactic acid bacteria produce bacteriocins that may reduce the risk of ascending infections. It has also been proposed that the vaginal microbiota has the potential to influence the conception process by influencing the local production of proinflammatory cytokines which in turn impact the survival rate and motility of sperm cells.
The vaginal microbiome and Vulvodynia Several microorganisms have been discussed for presumed role in LPV development: LPV is frequently associated with preceding chronic recurrent candidiasis, LPV may be produced in a mouse model by repeated vulvovaginal fungal infection, the difficulty in treating women with concomitant LPV and candidiasis (complicated LPV), the reports of the beneficial effect of treatment with combined antibiotics, aimed at eradicating H. pylori peptic condition (although H. pylori has not been detected in LPV tissues).
Indirect evidence of the role of the microbiome with the development of LPV may be deduced from the beneficial effect (14.3 - 50%), reported by some authors, of a diet avoiding oxalate and rich in Calcium citrate, on LPV. As women with LPV consume more oxalate - although not significantly, we suspect that the variability in response rate may be due to the indirect effect of the diet - through changes in the microbiome, which may be affecting LPV severity. In addition, the adverse effect of oral contraceptive pills (OCP) in increasing LPV symptoms; OCP tend to change the composition of the vaginal microbiota, consequent to their effect of thinning and dehydrating the vaginal mucosa. These finding prompt us to further inquire the possible association of vaginal microbiome dysbiosis and the development of LPV.
Objective:
The proposed study will first compare the vaginal microbiome of women with severe LPV, not treated by diet and otherwise healthy, to women without LPV (we will also compare our results to the NIH HMP data). At the second stage we will characterize the effect of a three-month low oxalate diet on the vaginal microbiota of women with LPV and on the outcome compared to a group of patients with LPV not treated by diet. Vaginal pH and date of menstrual cycle will be checked. We propose that dysbiosis in the vaginal microbiota may trigger the development of LPV.
Vulvodynia subtype:
- The research will study women with localized provoked Vulvodynia
- Only secondary type of LPV will be included.
- LPV diagnosis will be based on documenting first two Friedrich's criteria for vulva vestibulits syndrome: patient's complaint of entry dyspareunia, a positive Q-tip test.
- Only women suffering from levels II or III dyspareunia according to Marinoff : Level II is where the pain prevents intercourse from taking place on most occasions; and Level III where pain results in total apareunia.
Methods/Protocol This will be a double blind, prospective study comparing the microbiome of women with severe LPV to women without LPV, and to compare the effect of consuming the low oxalate diet with calcium citrate supplements for one month on the microbiome of women with LPV.
The local Institutional Review Board approval has been requested. Every woman participating in the study will sign an informed consent prior to enrollment.
Study group
The study group will consist of 35 women:
- Meeting first two Friedrich's criteria for vulva vestibulitis syndrome
- Diagnosed by a gynecological examination with Localized Provoked Vulvodynia
- Diagnosed with a Level II or III degree of the syndrome according to Marinoff Control group
- The control group will consist of 35 consecutive women who are referred to the departments of the co-investigators. Presentation of LPV is an exclusion criterion.
Materials and Methods:
Prior to enrollment, the women will be questioned about possible inclusion and exclusion criteria, and fill in the ISSVD Vulvodynia questionnaire.
Women found suitable for the study will undergo a Q-tip test to confirm the diagnosis of Vestibulodynia. Women of the LPV group will be instructed to consume a "low oxalate diet" with calcium citrate supplements, as recommended by Solomons et al for the duration of at least one month, to assess its impact on the vaginal microbiome.
Clinical pain scores and vulvar sensitivity by Q-tip test will be repeated after one month and compared to the clinical pain scores at the beginning of the study. Subjective evaluation will be carried out by comparing personal data from questionnaires filled in at enrollment and one month later.
Clinical evaluation will be performed by an experienced vulvar expert, using the pain intensity scale (The 11 points (0-10) pain intensity numerical rating scale-PI-NRS), in seven foci throughout the vestibule (the Q-tip test) and by comparing patients' responses to questionnaires evaluating pain during intercourse or other activities (riding a bicycle/horse), before and after diet.
- Conditions
- Vulvodynia, Vulvar Vestibulitis
- Being tested
- Low Oxalate Diet
- Keywords
- vestibulitis, microbiome
- Medical subject headings
- Vulvodynia, Vulvar Vestibulitis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Low Oxalate DietDietary supplement
Low oxalate diet is a diet where products with oxalate will be eliminated, such as: tomatoes, berries, coffee, nuts
| Study group | Role | What they receive |
|---|---|---|
| Study A - with diet | Active comparator | Patients with LPV, treated by Low Oxalate Diet for three months. Receives: Dietary Supplement: Low Oxalate Diet |
| Study B- no diet | Active comparator | Patients with LPV, not treated by Low Oxalate Diet for three months. Receives: Dietary Supplement: Low Oxalate Diet |
| Control | Active comparator | Healthy women without LPV, not treated by Low Oxalate Diet Receives: Dietary Supplement: Low Oxalate Diet |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in vaginal microbiome composition of women with localized provoked vulvodynia following three months of low oxalate diet
The microbiome components will be examined before and after the diet by characterization of the genomic components of the bacterial communities
Measured: Within one week after three months of low oxalate diet
Secondary outcomes (1)
Level of dyspareunia following three months of low oxalate diet in women with localized provoked vulvodynia
The level of vestibular tenderness will be examined before and after the diet
Measured: Within one week after three months of low oxalate diet
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Mar 2015 (estimated)
- Study startMar 2015
- Primary completionFeb 2016 (estimated)
- Study completionFeb 2017 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for VulvodyniaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 70 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Western Galilee Hospital-Nahariya
- Sponsor type
- Other government
- Responsible party
- Principal investigator, Prof. Jacob Bornstein, Western Galilee Hospital-Nahariya
- Investigators
- Jacob Bornstein, MD, Principal investigator, Western Galilee Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02393911
- Sponsor's protocol ID
- 0146-14-NHR
- Acronym
- DMLPV
- Status last verified
- Mar 2015
- First submitted
- 27 Jan 2015
- Last updated
- 20 Mar 2015
- Results posted
- No
- Data monitoring committee
- No
Publications
Awad-Igbaria Y, Palzur E, Nasser M, Vieira-Baptista P, Bornstein J. Changes in the Vaginal Microbiota of Women With Secondary Localized Provoked Vulvodynia. J Low Genit Tract Dis. 2022 Oct 1;26(4):339-344. doi: 10.1097/LGT.0000000000000689. Epub 2022 Aug 6.
PubMed 35943448
Study at a glance
From the registry record, last updated by the sponsor on 20 Mar 2015. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Dysbiosis in the Vaginal Microbiota May be Associated With the Development of Localized Provoked Vulvodynia (LPV)
- ClinicalTrials.gov ID
- NCT02393911
- Acronym / sponsor ID
- DMLPV / 0146-14-NHR
- Conditions
- Vulvodynia, Vulvar Vestibulitis
- Keywords
- vestibulitis, microbiome
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 70 participants (estimated)
- Lead sponsor
- Western Galilee Hospital-NahariyaOther government
- Study start
- Mar 2015
- Primary completion
- Feb 2016 (estimated)
- Study completion
- Feb 2017 (estimated)
- First posted
- 20 Mar 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Currently, the pathogenesis of Localized Provoked Vulvodynia (LPV) has not been elucidated. Few observations may point to involvement of the microbiome: the association of LPV with preceding chronic recurrent candidiasis, and the reports of the beneficial effect of a diet avoiding oxalate on Vulvodynia.
Studies in the new field of microbiome research focus on the composition of overall microorganisms in our body and their impacts on our health. Changes in the composition of the vaginal microbiota (dysbiosis) have been linked with different health and disease states. We have also shown recently that women can be divided into 2 groups according to the composition of their vaginal microbiome.
The proposed study will compare the vaginal microbiome of women with severe LPV, not treated by diet and otherwise healthy, to women without LPV (we will also compare our results to the NIH HMP data). Vaginal pH and date of menstrual cycle will be checked. We propose that dysbiosis in the vaginal microbiota may trigger the development of LPV.
Detailed description
Vulvodynia - vulvar pain. The exact etiology has not been elucidated yet, and therapy is often unsatisfactory. Two main types of Vulvodynia exist, with the far more common type being Localized provoked vulvodynia (LPV), also known as Vestibulodynia, and in the past - Vestibulitis. This study will concentrate on this common disorder which affects young women, whose quality of life deteriorate significantly by the inability to experience vaginal sex.
The vaginal microbiome The new field of microbiome research focuses on the composition of overall microorganisms in the human body and their impacts on our human health. Amazingly, the number of microbial cells within our body is 10 times greater than the sum of all our human somatic and germ cells, and they carry 150 times more genetic information than our own. Changes in the composition of the vaginal microbiota (dysbiosis) have been linked with different health and disease states.
The vagina is colonized with around 108-109 bacteria/mL vaginal fluid which is comparable to the small intestine. Recently, the NIH Human Microbiome Project characterized the bacterial communities across the human body and found that the vagina harbors low complexity bacterial communities. These communities had the lowest alpha diversity (within sample diversity) among the different body sites and low beta diversity (between sample diversity) at the genus level. This diversity was high at the species level due to distinct Lactobacillus spp. The communities were sampled at the sub sites that included the posterior fornix, mid vagina and the vaginal introitus. There was little distinction between the three sites hence we will focus on posterior fornix. The vaginal communities of healthy women, have also been repeatedly observed to occupy one of five states, four dominated by Lactobacillus spp. and one by higher overall microbial diversity. Shifts between the community structures within individuals (dysbiosis) are associated with disease states so it would be interesting to study whether women with LPV belong to a different enterotype than healthy women.
The vaginal microbial communities have been shown to change during different stages in a woman's life and to influence pregnancy. As early as 1930, Cruickshank and Baird described changes in the vaginal bacterial communities that occurred between the 5th and 7th month of pregnancy.
In 2010 a study was undertaken among Amerindian women to examine the microbial vaginal signature at term in relation to delivery mode (n=9). Variability in vaginal taxa was noted between subjects particularly for Lactobacillus species. Metagenomic analysis of the vaginal microbiome in a cross-sectional study of 24 healthy pregnant women and 60 non-pregnant controls at three vaginal sites (introitus, posterior fornix and midvagina) found the richness and diversity of the vaginal microbiome to be reduced in pregnancy in ways that did not appear to be driven by BMI, race or ethnicity . As pregnancy progressed and as proximity to the uterus increased, less diversity and richness were noted. Lactobacillus species were enriched in pregnancy, which the authors postulated may be biologically significant as lactic acid bacteria produce bacteriocins that may reduce the risk of ascending infections. It has also been proposed that the vaginal microbiota has the potential to influence the conception process by influencing the local production of proinflammatory cytokines which in turn impact the survival rate and motility of sperm cells.
The vaginal microbiome and Vulvodynia Several microorganisms have been discussed for presumed role in LPV development: LPV is frequently associated with preceding chronic recurrent candidiasis, LPV may be produced in a mouse model by repeated vulvovaginal fungal infection, the difficulty in treating women with concomitant LPV and candidiasis (complicated LPV), the reports of the beneficial effect of treatment with combined antibiotics, aimed at eradicating H. pylori peptic condition (although H. pylori has not been detected in LPV tissues).
Indirect evidence of the role of the microbiome with the development of LPV may be deduced from the beneficial effect (14.3 - 50%), reported by some authors, of a diet avoiding oxalate and rich in Calcium citrate, on LPV. As women with LPV consume more oxalate - although not significantly, we suspect that the variability in response rate may be due to the indirect effect of the diet - through changes in the microbiome, which may be affecting LPV severity. In addition, the adverse effect of oral contraceptive pills (OCP) in increasing LPV symptoms; OCP tend to change the composition of the vaginal microbiota, consequent to their effect of thinning and dehydrating the vaginal mucosa. These finding prompt us to further inquire the possible association of vaginal microbiome dysbiosis and the development of LPV.
Objective:
The proposed study will first compare the vaginal microbiome of women with severe LPV, not treated by diet and otherwise healthy, to women without LPV (we will also compare our results to the NIH HMP data). At the second stage we will characterize the effect of a three-month low oxalate diet on the vaginal microbiota of women with LPV and on the outcome compared to a group of patients with LPV not treated by diet. Vaginal pH and date of menstrual cycle will be checked. We propose that dysbiosis in the vaginal microbiota may trigger the development of LPV.
Vulvodynia subtype:
- The research will study women with localized provoked Vulvodynia
- Only secondary type of LPV will be included.
- LPV diagnosis will be based on documenting first two Friedrich's criteria for vulva vestibulits syndrome: patient's complaint of entry dyspareunia, a positive Q-tip test.
- Only women suffering from levels II or III dyspareunia according to Marinoff : Level II is where the pain prevents intercourse from taking place on most occasions; and Level III where pain results in total apareunia.
Methods/Protocol This will be a double blind, prospective study comparing the microbiome of women with severe LPV to women without LPV, and to compare the effect of consuming the low oxalate diet with calcium citrate supplements for one month on the microbiome of women with LPV.
The local Institutional Review Board approval has been requested. Every woman participating in the study will sign an informed consent prior to enrollment.
Study group
The study group will consist of 35 women:
- Meeting first two Friedrich's criteria for vulva vestibulitis syndrome
- Diagnosed by a gynecological examination with Localized Provoked Vulvodynia
- Diagnosed with a Level II or III degree of the syndrome according to Marinoff Control group
- The control group will consist of 35 consecutive women who are referred to the departments of the co-investigators. Presentation of LPV is an exclusion criterion.
Materials and Methods:
Prior to enrollment, the women will be questioned about possible inclusion and exclusion criteria, and fill in the ISSVD Vulvodynia questionnaire.
Women found suitable for the study will undergo a Q-tip test to confirm the diagnosis of Vestibulodynia. Women of the LPV group will be instructed to consume a "low oxalate diet" with calcium citrate supplements, as recommended by Solomons et al for the duration of at least one month, to assess its impact on the vaginal microbiome.
Clinical pain scores and vulvar sensitivity by Q-tip test will be repeated after one month and compared to the clinical pain scores at the beginning of the study. Subjective evaluation will be carried out by comparing personal data from questionnaires filled in at enrollment and one month later.
Clinical evaluation will be performed by an experienced vulvar expert, using the pain intensity scale (The 11 points (0-10) pain intensity numerical rating scale-PI-NRS), in seven foci throughout the vestibule (the Q-tip test) and by comparing patients' responses to questionnaires evaluating pain during intercourse or other activities (riding a bicycle/horse), before and after diet.
Study design
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Study A - with diet | Active comparator | Dietary Supplement: Low Oxalate DietPatients with LPV, treated by Low Oxalate Diet for three months. |
| Study B- no diet | Active comparator | Dietary Supplement: Low Oxalate DietPatients with LPV, not treated by Low Oxalate Diet for three months. |
| Control | Active comparator | Dietary Supplement: Low Oxalate DietHealthy women without LPV, not treated by Low Oxalate Diet |
Who may qualify
- Ages
- 18 to 50 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (1 listed)
- Healthy women, aged 18-50 years, meet Friedrich's first two criteria for vulvar Vestibulitis syndrome, suffer from levels II or III dyspareunia according to Marinoff
Key exclusion criteria (1 listed)
- Women suffering from generalized Vulvodynia (constant vulvar pain - unrelated to provocation), pregnant or lactating. Women will also be excluded from the study if they were have any medical condition, acute or chronic, or anticipated not being available for the one month follow up visit, have received antibiotics during the month preceding the study.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Low Oxalate DietLow oxalate diet is a diet where products with oxalate will be eliminated, such as: tomatoes, berries, coffee, nuts | Dietary supplement | Control, Study A - with diet, Study B- no diet |
Primary outcome
Change in vaginal microbiome composition of women with localized provoked vulvodynia following three months of low oxalate diet
Time frame: Within one week after three months of low oxalate diet
The microbiome components will be examined before and after the diet by characterization of the genomic components of the bacterial communities
1 secondary outcome
Level of dyspareunia following three months of low oxalate diet in women with localized provoked vulvodynia
Time frame: Within one week after three months of low oxalate diet
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Mar 2015.
- Derived from this study: PubMed 35943448Awad-Igbaria Y, Palzur E, Nasser M, Vieira-Baptista P, Bornstein J. Changes in the Vaginal Microbiota of Women With Secondary Localized Provoked Vulvodynia. J Low Genit Tract Dis. 2022 Oct 1;26(4):339-344. doi: 10.1097/LGT.0000000000000689. Epub 2022 Aug 6.
Related trials for Vulvodynia
Active, not recruitingPhase 2
A Phase 2 Study to Evaluate the Efficacy and Safety of Pudafensine in Vulvodynia (Provoked Vestibulodynia)
Vulvodynia
Not yet recruiting
Integrated Care Pathway for Hormonally Mediated Vestibulodynia: a Feasibility and Acceptability Pilot
Vestibulodynia, Vulvodynia
Active, not recruiting
Vestibulectomy Surgical Techniques Comparison Study
Vulvar Pain, Vulvodynia
Not yet recruiting
Transcutaneous Genital Nerves Stimulation for the Treatment of Refractory Chronic Pelvic and Genital Pain in Women.
Refractory Visceral Pelvic Pain, Refractory Genital Pain
Not yet recruitingPhase 2
A Pilot Study on the Efficacy of Oral Low Dose Naltrexone for Vulvodynia
Vulvodynia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Jacob Bornstein, MD principal investigator
Western Galilee Hospital
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Low Oxalate Diet in people with Vulvodynia and Vulvar Vestibulitis, run by Western Galilee Hospital-Nahariya.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 20 Mar 2015. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Manal Nasser, MD (972546738094, manalnas@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in vaginal microbiome composition of women with localized provoked vulvodynia following three months of low oxalate diet (time frame: Within one week after three months of low oxalate diet). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02393911, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Mar 2015.